Chapter 18 — Exercises

TB-500, Thymosin Alpha-1, and Other Recovery and Immune Peptides

These exercises are for working, not for grading. No answers are supplied here; several questions have more than one defensible response, and the reasoning is what matters.

Items marked † are extended: they take longer, require you to hold two ideas in tension, or ask you to write something you would be willing to say out loud to a person who disagrees with you.

Sections A through H run roughly in chapter order. Section I is synthesis across Part III.

A. The parent and the fragment (§18.1)

A1. In your own words, state the difference between thymosin β4 and the compound marketed as TB-500. Do it in two sentences, without using the word "basically."

A2. A product description reads: "TB-500 (Thymosin Beta-4) — extensively studied for tissue repair." Rewrite that sentence so it is accurate. Note how much longer your version is, and write one sentence about why the inaccurate version is more commercially useful.

A3. Explain why "the actin-binding region is the active part, so the fragment should work" is an argument that Rule 3 of the rating system will not accept. Then explain what kind of evidence would be accepted for the same conclusion.

A4. † §18.1 lists a chain of five assumptions running from animal data on the parent molecule to a clinical outcome in a person. Write out all five in your own words. Then, for each one, name the single piece of information that would let you check it, and note whether that information is ordinarily available to a consumer.

A5. Chapter 1 §1.8 says a compound known only by a laboratory code has told you something about its regulatory history. State precisely what it has told you, and state precisely what it has not told you. Both halves are required.

A6. Thymosin β4 is 43 residues. Using Chapter 1 §1.5, explain why some sources call it a peptide and some call it a small protein, and say whether anything about this chapter's argument changes depending on which label is used.

B. Reading the animal literature (§18.2)

B1. Name the three areas of injury biology in which thymosin β4's animal literature is concentrated. For each one, name a reason that model might fail to represent the corresponding human situation.

B2. Chapter 5 §5.3 lists five reasons animal results fail to transfer. List all five from memory, then check yourself against §18.2. Which one did you forget? Most people forget the same one.

B3. Explain, to someone who has never thought about it, why the absence of a registry for animal research means the published animal literature has "no denominator." Use an analogy that does not involve science.

B4. This book states that it will not tell you how many animal studies exist for any compound. Give the reason. Then give a reason someone might object to that policy, and say whether you find the objection persuasive.

B5. † Figure 18.1 is explicitly labeled as an illustrative composite rather than a real study. Write a short defense of that choice — why a textbook might teach a design with a constructed example — and then write the strongest objection to it. Which do you find more convincing, and what would make the composite acceptable to a reader who was initially suspicious?

B6. A colleague says: "If we just ran enough high-quality animal studies, eventually we'd have enough evidence to skip the human trial." Respond in three sentences.

B7. † Take the ❌ rating in §18.2 and rewrite all four fields as if a single small randomized human trial of the marketed fragment had been completed with a positive result on a pain-and-function endpoint. What rating do you now give, and what does your "what would change it" field say?

C. Split regulatory status (§18.3)

C1. State the fact about thymosin alpha-1's approval status in one sentence, including both halves.

C2. §18.3 describes two common but wrong readings of a split regulatory status. Name both, then name the hidden premise they share.

C3. Using the three-row diagram in §18.3, classify each of the following: (a) insulin for type 1 diabetes; (b) a compound sold in supplement channels with no approval anywhere and no submitted dossier; (c) thymosin alpha-1. For each, say what the classification tells you and what it does not.

C4. Why does a jurisdiction's disease burden affect a regulatory decision that is nominally about whether a drug works? Is that a flaw in the system or a feature? Argue one side in five sentences.

C5. † A patient says: "It's approved in a dozen countries — the FDA is just behind." Write the reply you would actually give: it must acknowledge what is true in the statement, correct what is not, avoid condescension, and end somewhere more useful than a disagreement. Aim for under 150 words.

C6. §18.3 says a rating system that never produces a middle rating "is not a rating system, it is a sorting hat." Explain what failure mode that line is warning against, and describe how you would tell, from the outside, whether a source's ratings had that problem.

D. LL-37 and the handoff (§18.4)

D1. State LL-37's two distinct activities, and explain why one of them yields testable claims more easily than the other.

D2. §18.4 explicitly declines to rate LL-37 and defers to Chapter 25. Give the stated reason, and connect it to Rule 5 of the rating system.

D3. A membrane-disrupting mechanism does not perfectly distinguish bacterial membranes from human ones. Explain why this makes "it's a natural human peptide, so it's safe" a poor argument, and identify which Chapter 1 callout you are echoing.

D4. † Design — in prose, not as a protocol — a claim about LL-37 that would satisfy all five specifications from §18.6. Then write the unfalsifiable version of the same underlying idea, the way a marketing page would put it. Put them side by side and annotate what was lost.

E. Gut peptides and the absorption question (§18.5)

E1. KPV is a fragment of α-MSH. Explain why §18.5 treats KPV's fragment status differently from TB-500's, and what specific fact makes the difference.

E2. State, in one sentence, why larazotide's non-absorption is a design specification rather than a failure.

E3. For each of the following claimed effects, say whether the "it acts locally in the gut" defense is available: (a) reducing intestinal permeability; (b) accelerating tendon healing; (c) altering gut motility; (d) increasing muscle protein synthesis. Give your reasoning in one line each.

E4. §18.5 says the first question about any oral peptide is "where does it need to get to?" rather than "can it be absorbed?" Explain why the order matters, and give an example — from any chapter — where asking them in the wrong order produces the wrong conclusion.

E5. † Larazotide has been through human clinical trials; KPV's literature is preclinical. Both are rated 🔬. Write a paragraph arguing that they should carry different ratings, then a paragraph defending the single shared rating. Which position do you hold, and what would settle it?

F. The unfalsifiable claim (§18.6)

F1. Write out the five things a real immune claim must specify. Do it from memory first.

F2. For each of the following, say whether it is falsifiable as stated, and if not, name the missing specification: (a) "boosts immunity"; (b) "increases natural killer cell counts in adults receiving chemotherapy"; (c) "restores immune balance"; (d) "reduces laboratory-confirmed respiratory infections in adults over 65 across one season"; (e) "supports healthy immune function."

F3. Explain why "it doesn't suppress or stimulate — it balances" is a more sophisticated failure than a simple exaggeration.

F4. A study reports that a compound significantly raised one circulating immune cell population in healthy volunteers. The claim satisfies four of the five specifications. Which one is missing, and why does its absence matter more than it appears to?

F5. † Chapter 10 §10.9 diagnosed "anti-inflammatory" and §18.6 diagnoses "immune modulation." Identify the shared structure of the two failures, state it as a general rule, and then find two examples of the same structure in a domain this book does not cover — nutrition, fitness, mental health, or finance. Explain what makes each one unfalsifiable.

F6. §18.6 rates a claim form rather than a molecule. Explain why the "what would change it" field for that rating says that nothing could change it, and why that is not a cop-out.

F7. † Take a real product description for any "immune support" product — peptide or otherwise — and rewrite it twice. Version one: the most generous falsifiable claim the underlying idea could support. Version two: what the evidence, as presented on the page, actually licenses. Note the distance between your two versions and write one sentence about what fills that gap commercially.

G. The symmetric risk (§18.7)

G1. Name the three mechanisms that appear in nearly every pro-healing promotional story, and state what else those three mechanisms are required for.

G2. Write the sentence "pro-healing is pro-growth" as a full argument in four steps. Then identify which step, if any, is an empirical claim rather than a definitional one.

G3. §18.7 forbids two moves: asserting a cancer link, and dismissing the concern. Explain what is wrong with each, and name the rating rule that each move would violate.

G4. Explain why "no link has been demonstrated" is a weaker reassurance for an unstudied compound than for a drug that has been marketed and monitored for twenty years.

G5. † Rule 3 says mechanism cannot upgrade a rating. §18.7 says mechanism can legitimately raise a safety question. Some readers will call this a double standard. Write the objection at its strongest, then answer it. Your answer must turn on what each kind of claim asserts rather than on which conclusion you prefer.

G6. † A person with a prior malignancy in remission asks about a repair peptide. Write what you would say — accurate about the mechanism, silent on links that have not been established, honest that the question is unstudied, and pointing somewhere more useful than "ask your doctor." Then write what you would want their oncologist to know that you could not have told them.

H. The dossier when evidence is thin

H1. Name the three states that "no evidence" wrongly merges, and give a one-line diagnostic question for each.

H2. Explain why state (C) — studied in a different molecule — is described as the most dangerous. What does it feel like from the inside, and why does that feeling mislead?

H3. For a compound of your choice from your own dossier, complete Field 5 using the two worked demonstrations as models. Include the two separate confidence lines.

H4. † The TB-500 and thymosin alpha-1 demonstrations differ on almost every line. Build a side-by-side table of the differences and identify the single line that carries the most information about how much weight to place on each compound. Defend your choice against the two next-best candidates.

H5. Write your "trigger sentence" — the specific finding that would change your assessment — for two compounds: one you are inclined to believe in, and one you are inclined to dismiss. Compare how easy each was to write. What does the difference tell you?

I. Synthesis across Part III

I1. BPC-157 (Ch. 17) and TB-500 both rate ❌ for human repair claims. Name every feature the two situations share, then every feature that differs. Which list is longer?

I2. † Chapter 17 established the template for an honest ❌: take the animal work seriously, state the human situation accurately, explain why both are true, never sneer. Grade this chapter against that template on each of the four elements. Where does it come closest to failing, and what would you change?

I3. Rank the five compounds in this chapter by the amount of human evidence available for the claims people actually make about them. Then rank them by how confidently those claims are marketed. Comment on the correlation.

I4. This chapter argues that the "recovery and immune peptides" category has no evidentiary content. Construct the strongest case for the category being useful, then say what it would take for that case to succeed.

I5. † Write a one-page briefing, for a reader who has read no part of this book, that conveys the two central ideas of this chapter — the parent/fragment distinction and the unfalsifiable immune claim — without using the words "falsifiable," "epistemic," or "surrogate." Your reader is intelligent and busy and has already bought some of these compounds. Do not moralize.